NO930881D0 - ANTI-TUMOR COMPOUNDS - Google Patents

ANTI-TUMOR COMPOUNDS

Info

Publication number
NO930881D0
NO930881D0 NO930881A NO930881A NO930881D0 NO 930881 D0 NO930881 D0 NO 930881D0 NO 930881 A NO930881 A NO 930881A NO 930881 A NO930881 A NO 930881A NO 930881 D0 NO930881 D0 NO 930881D0
Authority
NO
Norway
Prior art keywords
alkyl
quinazoline
pharmaceutically
hydrogen
tumor compounds
Prior art date
Application number
NO930881A
Other languages
Norwegian (no)
Other versions
NO930881L (en
NO301543B1 (en
Inventor
Stephen John Pegg
James Michael Wardleworth
Original Assignee
Zeneca Ltd
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, British Tech Group filed Critical Zeneca Ltd
Publication of NO930881D0 publication Critical patent/NO930881D0/en
Publication of NO930881L publication Critical patent/NO930881L/en
Publication of NO301543B1 publication Critical patent/NO301543B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity; to processes for their manufacture; and to pharmaceutical compositions containing them. The invention provides a quinazoline of the formula:- <CHEM> wherein R<1> is (1-4C)alkyl; the quinazoline ring may optionally bear one or two further substituents selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy; R<2> is hydrogen or (1-4C)alkyl; R<3> includes hydrogen and (1-4C)alkyl; and Ar is optionally substituted phenylene or heterocyclene; or a pharmaceutically-acceptable salt or ester thereof.
NO930881A 1992-03-11 1993-03-10 2- £ 4- (quinazolinylmethylamino) benzamido | -4- (tetrazolyl) butyric acid derivatives with anti-tumor activity NO301543B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929205320A GB9205320D0 (en) 1992-03-11 1992-03-11 Anti-tumour compounds

Publications (3)

Publication Number Publication Date
NO930881D0 true NO930881D0 (en) 1993-03-10
NO930881L NO930881L (en) 1993-09-13
NO301543B1 NO301543B1 (en) 1997-11-10

Family

ID=10711936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO930881A NO301543B1 (en) 1992-03-11 1993-03-10 2- £ 4- (quinazolinylmethylamino) benzamido | -4- (tetrazolyl) butyric acid derivatives with anti-tumor activity

Country Status (22)

Country Link
US (1) US5955463A (en)
EP (1) EP0562734B1 (en)
JP (1) JP3160111B2 (en)
KR (1) KR100221011B1 (en)
AT (1) ATE131823T1 (en)
AU (1) AU659277B2 (en)
CA (1) CA2090942C (en)
CZ (1) CZ281811B6 (en)
DE (1) DE69301048T2 (en)
DK (1) DK0562734T3 (en)
ES (1) ES2081178T3 (en)
FI (1) FI108793B (en)
GB (2) GB9205320D0 (en)
GR (1) GR3018501T3 (en)
HK (1) HK21297A (en)
HU (1) HU211127A9 (en)
IL (1) IL104984A (en)
NO (1) NO301543B1 (en)
NZ (1) NZ247122A (en)
RU (1) RU2111209C1 (en)
TW (1) TW223635B (en)
ZA (1) ZA931447B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
WO1996040648A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
EP1049786A2 (en) 1998-01-21 2000-11-08 Sugen, Inc. Human orthologues of wart
DE69926742T2 (en) 1998-04-14 2006-06-14 Sugen Inc STE20-RELATED PROTEIN KINASES
US6235213B1 (en) * 1998-05-18 2001-05-22 Micron Technology, Inc. Etching methods, methods of removing portions of material, and methods of forming silicon nitride spacers
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
JP2003512838A (en) 1999-10-22 2003-04-08 ファルマシア・アンド・アップジョン・カンパニー Drosophila G-protein coupled receptors, nucleic acids, and related methods.
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
ATE526028T1 (en) 2001-08-31 2011-10-15 Btg Int Ltd USE OF CYCLOPENTAÄGÜCHINAZOLINE DERIVATIVES FOR CANCER TREATMENT
EP2332962A1 (en) 2001-08-31 2011-06-15 BTG International Limited Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions
GB0317631D0 (en) * 2003-07-28 2003-08-27 Btg Int Ltd Synthetic method
WO2007068895A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA807909B (en) * 1979-12-19 1981-12-30 Nat Res Dev Anti-cancer quinazoline derivatives
GB2065653B (en) * 1979-12-19 1983-03-09 Nat Res Dev Anti-cancer quinazoline derivatives
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4725687A (en) * 1986-04-28 1988-02-16 Southern Research Institute 5-methyl-5-deaza analogues of methotrexate and N10 -ethylaminopterin
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
US4999424A (en) * 1988-11-10 1991-03-12 The Pennsylvania State University GAR transformylase inhibitor
US5252573A (en) * 1988-12-15 1993-10-12 Imperial Chemical Industries Plc Anti-tumor agents
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
IL98167A0 (en) * 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
US5145854A (en) * 1991-11-27 1992-09-08 Nair Madhavan G 1-formyl-5,8,10-trideazafolates

Also Published As

Publication number Publication date
NO930881L (en) 1993-09-13
GB9205320D0 (en) 1992-04-22
GR3018501T3 (en) 1996-03-31
EP0562734B1 (en) 1995-12-20
HU211127A9 (en) 1995-10-30
IL104984A (en) 1998-01-04
CZ281811B6 (en) 1997-02-12
CA2090942A1 (en) 1993-09-12
GB2264946A (en) 1993-09-15
ZA931447B (en) 1993-09-13
HK21297A (en) 1997-02-27
DE69301048T2 (en) 1996-05-15
FI108793B (en) 2002-03-28
RU2111209C1 (en) 1998-05-20
AU659277B2 (en) 1995-05-11
DE69301048D1 (en) 1996-02-01
TW223635B (en) 1994-05-11
ATE131823T1 (en) 1996-01-15
AU3378293A (en) 1993-09-16
FI931067A (en) 1993-09-12
CZ36293A3 (en) 1994-01-19
GB2264946B (en) 1995-05-17
GB9304807D0 (en) 1993-04-28
NO301543B1 (en) 1997-11-10
KR100221011B1 (en) 1999-09-15
NZ247122A (en) 1995-07-26
FI931067A0 (en) 1993-03-10
CA2090942C (en) 2000-02-08
US5955463A (en) 1999-09-21
JPH06279438A (en) 1994-10-04
KR930019667A (en) 1993-10-18
IL104984A0 (en) 1993-07-08
ES2081178T3 (en) 1996-02-16
JP3160111B2 (en) 2001-04-23
EP0562734A1 (en) 1993-09-29
DK0562734T3 (en) 1996-05-06

Similar Documents

Publication Publication Date Title
NO930881D0 (en) ANTI-TUMOR COMPOUNDS
FI965020A0 (en) New compounds, processes for their preparation and anti-tumor agents
IL120266A (en) Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
ATE119774T1 (en) IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF.
MY129970A (en) Hypolipidaemic compounds
BRPI0209216B8 (en) quinoline and quinazoline derivatives, pharmaceutical compositions comprising the same and their uses
DK0444659T3 (en) Pharmaceutical solution containing derivatives of FK 506
DK0918776T3 (en) Total synthesis of antitumor acylfulvenes
DK0490566T3 (en) Preparation and use of N-iodopropargyloxycarbonylamino acid esters and derivatives as antimicrobial agents
FI943508A0 (en) Pyridinecarboxymidamide compounds and their use
EA200400758A1 (en) NEW COMPOUNDS OF BENZOTHIAZINE AND BENZOTHIADIAZINE, METHOD OF THEIR RECEIVING AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
ATE134371T1 (en) FUNGICIDAL FURANONE DERIVATIVES
ATE189813T1 (en) PROSTAGLANDIN-I ANALOGUE
TW258661B (en)